Report Overview

Indian Novel Treatment in Epilepsy Therapeutics Market size stood at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period

India carries an enormous burden of epilepsy. Around 1012 million people with epilepsy reside in India. A significant proportion of PWE do not receive appropriate treatment, leading to a large treatment gap (TG). Poor awareness of antiepileptic drugs (AEDs), cultural practices, social stigma surrounding epilepsy, lack of accessibility to healthcare, and a severe shortage of medical professionals trained in the management of epilepsy are major contributors to the TG. The overall prevalence of epilepsy in India is 5.59-10 per 1000. The age-adjusted prevalence ratio of active epilepsy in Kerala is 4.7 per 1000 population. Epilepsy is a central nervous system (CNS) disorder in which brain activity becomes abnormal, resulting in seizures or periods of unusual behavior, and sensations. It can occur due to a genetic disorder or an acquired brain injury. In addition to the rising cases of epilepsy, there is a rising effort taken to increase awareness about the condition. Rising support from governments and several companies can help in the fight against this highly contagious disease. There is also rising awareness levels about epilepsy coupled with strategic alliances that are anticipated to stimulate the market growth.



Market Drivers

The increasing rate of epilepsy prevalence in the geriatric community and the rise in accident-induced brain injury cases are major factors driving market growth. The high sensitivity risk of elderly epilepsy is expected to fuel consumer demand. The rising awareness levels about epilepsy coupled with strategic alliances are anticipated to stimulate the market growth. The awareness initiatives by epilepsy networks have led to an increase in demand for better diagnosis and effective treatment of the disease. In addition, brain damage that can cause post-traumatic epilepsy (PTE) and post-traumatic seizures (PTS) can fuel demand in the epilepsy industry. The demand for epilepsy is also influenced by primary factors such as developing experimental medicines, the arrival of new drugs and the prevalence of neurological disorders such as meningitis and tumors. This rise is further fueled by an improvement in healthcare prices and an increase in disposable income.